Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987037 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL29986539 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL6440343 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL1468174 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL5980144 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL38558 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL38557 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL1468176 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL16635360 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL6440341 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1047 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2024-11-07 | — | — | US | claimed |
| US-20240353431-A1 | SELECTIVE MEASUREMENT OF HUMAN FACTOR VIII | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-24 | — | — | US | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| EP-4358989-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | Ohio State Innovation Foundation (US) | 2024-05-01 | — | — | EP | claimed |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2024-04-04 | — | — | US | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| WO-2022271810-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2022-12-29 | — | — | WO | claimed |
| WO-2022148974-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| US-11198715-B2 | Selective Bfl-1 peptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-14 | — | — | US | claimed |
| CN-1119650-A | Motilin-like polypeptides having gastrointestinal motility stimulating activity | OHMEDA PHARMA PROD (US) | 1996-04-03 | — | — | CN | claimed |
| EP-0699074-A1 | THROMBIN INHIBITORS | MERCK & CO. INC. (US) | 1996-03-06 | — | — | EP | claimed |
| US-5470830-A | Motilin-like polypeptides that inhibit gastrointestinal motor activity | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-11-28 | — | — | US | claimed |
| US-5422341-A | Antidiabetic agents | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-06-06 | — | — | US | claimed |
| EP-0647656-A1 | Motilin-like polypeptides that inhibit gastrointestinal motor activity | Ohmeda Pharmaceutical Products Division Inc. (US) | 1995-04-12 | — | — | EP | claimed |
| EP-0646601-A1 | Motilin-like polypeptides with gastrointestinal motor stimulating activity | Ohmeda Pharmaceutical Products Division Inc. (US) | 1995-04-05 | — | — | EP | claimed |
| WO-1994025051-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1994-11-10 | — | — | WO | claimed |
| EP-0061356-B1 | ANTAGONISTS OF THE ANTIDIURETIC AND/OR VASOPRESSOR ACTION OF ARGININE VASOPRESSIN | Medical College of Ohio (US) | 1985-07-17 | — | — | EP | claimed |
| US-4399125-A | CYCLIC OLIGOPEPTIDES | TRUSTEES OF COLUMBIA UNIVERSITY THE, A CORP. OF NY. | 1983-08-16 | — | — | US | claimed |
| EP-0061356-A2 | Antagonists of the antidiuretic and/or vasopressor action of arginine vasopressin | Medical College of Ohio (US) | 1982-09-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | KRAS, HRAS, NRAS | ALDH1A1 4357/4885NPSR1 1799/4885MEN1 242/4885 |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | PBK, KLRK1, MICA | ALDH1A1 4552/4885NPSR1 352/4885MEN1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.